Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma - Powles, Thomas (University of London. Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, Queen Mary) ; Motzer, Robert J. (Memorial Sloan Kettering Cancer Center) ; Escudier, Bernard (Gustave Roussy) ; Pal, Sumanta (City of Hope National Medical Center) ; Kollmannsberger, Christian (BCCA Vancouver Cancer Centre. British Columbia Cancer Agency) ; Pikiel, Joanna (Wojewodzkie Centrum Onkologii, 80-219 Gdańsk, Poland) ; Gurney, Howard (Macquarie University. Macquarie University and Westmead Hospital) ; Rha, Sun Young (Yonsei Cancer Center. Severance Hospital) ; Park, Se Hoon (Samsung Medical Center) ; Geertsen, Poul F. (Copenhagen University Hospital) ; Gross-Goupil, Marine (Groupe Hospitalier Saint André, 33000 Bordeaux, France) ; Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ; Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ; Markby, David W. (Exelixis, Inc) ; Arroyo, Alan (Exelixis, Inc) ; Dean, Mark (Exelixis, Inc) ; Choueiri, Toni K. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; George, Daniel (Duke University Medical Center) ; Universitat Autònoma de Barcelona